It’s no secret that boards want more data and information from chief compliance officers. Many directors consider regulatory, governance, and compliance risks at the top of the “needs-more-attention” list. Yet communicating effectively with the board is never easy.
Directors have limited time, and compliance officers must decide what information should rise to that level of reporting. Pfizer’s chief compliance officer Douglas Lankler addressed some of those difficulties at the Compliance Week 2011 conference in Washington last month.
